Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 80Neoplasms 14Neoplasm Metastasis 14Brain Neoplasms 9Breast Neoplasms, Male 7Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Stomach Neoplasms 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Lapatinib × Clear all
NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

University of Southern California

Phase 2 Terminated
15 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

NCT01700010 2013-01-17

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡